Will this be the first U.S. undertaking at Mariel?

Source : admin Mon Feb 20, 12:08 am EST
Two years after the Roswell Park Cancer Institute signed an agreement with Cuba’s Center for Molecular Immunology (CIM) to perform clinical trials of the lung cancer drug CIMAvax-EGF in the United States, a Roswell executive announced that the commercial arm of the Buffalo, N.Y.-based nonprofit is seeking investors to form a joint venture that will develop and manufacture this and other Cuban cancer drugs at a base in the Mariel Special Development Zone and bring them to the United States. Previous Top Stories
Thumb

Data & Maps

Previous entries
Cuba Standard.com Cuba News.com

ABOUT US | CONTACT US | PRIVACY POLICY
Copyright Cuba Standard